AKYNZEO® Outperforms Traditional Treatments for CINV
AKYNZEO® Shows Exceptional Efficacy in Managing CINV
AKYNZEO® has marked a significant advancement in the prevention of chemotherapy-induced nausea and vomiting (CINV), showing impressive results compared to the standard care protocol typically used for patients undergoing moderately emetogenic chemotherapy. The findings from the MyRisk clinical trial illustrate the potential of this innovative treatment in enhancing the quality of life for patients undergoing chemotherapy.
Overview of the MyRisk Clinical Trial
The MyRisk trial, a Phase IV, interventional, open-label, randomized trial, was conducted in seven countries and focused on evaluating the effectiveness of AKYNZEO®—a combination of netupitant and palonosetron—compared to the standard of care (SOC). The trial selected patients who are at increased risk of CINV based on a predictive risk factor algorithm, representing a pioneering approach in oncology care.
Significant Findings
Involving 388 participants, the primary goal of the MyRisk trial was to assess whether AKYNZEO® combined with dexamethasone (DEX) could yield better results than the conventional treatment of a 5-HT3 receptor antagonist plus DEX. Results clearly indicated that patients receiving the AKYNZEO® combination had significantly improved outcomes, achieving a complete response (CR) of 81.0% compared to 71.8% in the SOC group, a difference that underscores the efficacy of personalized treatment strategies.
Implications of the Study
Prof. Alex Molasiotis, a leading figure in the study, emphasized the importance of initiating optimal prophylaxis early in the treatment regimen. This proactive approach is crucial as CINV can become increasingly difficult to manage once it occurs, highlighting the importance of a tailored strategy to meet individual patient needs.
Expert Insights
Silvia Olivari, from Helsinn Group, also pointed out that the current treatment protocols often leave patients with insufficient care. With a considerable proportion of chemotherapy patients at risk for CINV, the necessity for tailored antiemetic prophylaxis is more pressing than ever. This customized approach significantly improves control over nausea, a common yet often overlooked complication of cancer treatment.
Presentation Details at ESMO
The compelling results from the MyRisk trial were shared at a prominent conference, emphasizing the significance of personalizing antiemetic prophylaxis. Here are the details:
Title: Personalizing Antiemetic Prophylaxis for Patients at High Emetic Risk: Results from the MyRisk Trial
Presentation Number: 2801O
Session Title: Supportive and palliative care
Date and Time: October 17, 2025, 16:00 – 17:30
Location: Hanover Auditorium, Hall 7.2c
Understanding AKYNZEO® and its Impact
AKYNZEO® stands out as the first approved fixed antiemetic combination that integrates both 5-HT3 and NK1 receptor antagonists. It's specifically designed for adult patients to prevent both acute and delayed nausea and vomiting associated with highly and moderately emetogenic chemotherapy treatments.
About Helsinn Group
Helsinn is a dedicated global pharmaceutical powerhouse that focuses on delivering innovative solutions to improve patient support in oncology and other chronic conditions. Since its inception in 1976, the company has remained family-owned and committed to its mission of enhancing quality of life for patients everywhere. With operations in multiple countries and a strong international presence, Helsinn continues to impact patient care significantly.
Frequently Asked Questions
What is the significance of the MyRisk trial?
The MyRisk trial showcases the effectiveness of AKYNZEO® over standard therapies, providing a tailored approach for patients at high risk of CINV.
How does AKYNZEO® work?
AKYNZEO® combines netupitant and palonosetron to effectively block the receptors responsible for nausea, thus enhancing patient outcomes during chemotherapy.
Why is personalized antiemetic therapy important?
Personalized therapy addresses individual patient risk factors, leading to better control of symptoms and improved overall patient satisfaction during treatment.
What does the recent study suggest about current treatment practices?
The study indicates that many patients currently receive inadequate care, highlighting the need for enhanced treatment protocols tailored to individual patient needs.
Where can I find more information about Helsinn Group?
Further details about Helsinn Group and their commitments to patient care can be found on their official website and social media platforms.
About The Author
Contact Henry Turner privately here. Or send an email with ATTN: Henry Turner as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
